

# Michael Van Ameringen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4482120/michael-van-ameringen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120  
papers

4,877  
citations

38  
h-index

67  
g-index

140  
ext. papers

5,689  
ext. citations

4.7  
avg, IF

5.39  
L-index

#	Paper	IF	Citations
120	Apps for mental health <b>2022</b> , 395-433		
119	Obsessive-compulsive disorder during the COVID-19 pandemic.. <i>Journal of Psychiatric Research</i> , <b>2022</b> , 149, 114-123	5.2	2
118	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network.. <i>Comprehensive Psychiatry</i> , <b>2022</b> , 116, 1523-1533	7.3	1
117	Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. <i>International Clinical Psychopharmacology</i> , <b>2021</b> , 36, 61-75	2.2	10
116	Binge eating disorder hidden behind a wall of anxiety disorders. <i>Journal of Psychiatry and Neuroscience</i> , <b>2021</b> , 46, E208-E209	4.5	0
115	Anxiety, depression and stress during the COVID-19 pandemic: Results from a cross-sectional survey. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 137, 96-103	5.2	25
114	Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. <i>Journal of Psychiatric Research</i> , <b>2021</b> , 140, 357-363	5.2	1
113	Mental health during the first wave of COVID-19 in Canada, the USA, Brazil and Italy. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2021</b> , 1-9	2.4	1
112	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. <i>International Clinical Psychopharmacology</i> , <b>2020</b> , 35, 173-193	2.2	22
111	Attitudes and Beliefs Toward Cannabis Before Recreational Legalization: A Cross-Sectional Study of Community Adults in Ontario. <i>Cannabis and Cannabinoid Research</i> , <b>2020</b> ,	4.6	1
110	Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users. <i>Comprehensive Psychiatry</i> , <b>2020</b> , 102, 152188	7.3	26
109	The role of cannabis in treating anxiety: an update. <i>Current Opinion in Psychiatry</i> , <b>2020</b> , 33, 1-7	4.9	10
108	Early detection and intervention for obsessive-compulsive disorder in childhood and adolescence. <i>The Lancet Child and Adolescent Health</i> , <b>2020</b> , 4, 99-101	14.5	8
107	Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. <i>Cognitive Behaviour Therapy</i> , <b>2020</b> , 49, 1-21	4.4	30
106	Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , <b>2020</b> , 25, 419-425	1.8	5
105	The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study. <i>Acta Psychiatrica Scandinavica</i> , <b>2020</b> , 142, 337-347	6.5	26
104	How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the European College of Neuropsychopharmacology. <i>Comprehensive Psychiatry</i> , <b>2020</b> , 103, 152174	7.3	93

103	Higher prevalence of irritable bowel syndrome and greater gastrointestinal symptoms in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , <b>2019</b> , 118, 1-6	5.2	11
102	Cannabis use behaviors and prevalence of anxiety and depressive symptoms in a cohort of Canadian medicinal cannabis users. <i>Journal of Psychiatric Research</i> , <b>2019</b> , 111, 134-139	5.2	31
101	Biological and psychosocial predictors of anxiety worsening in the postpartum period: A longitudinal study. <i>Journal of Affective Disorders</i> , <b>2019</b> , 250, 218-225	6.6	14
100	The gut microbiome in psychiatry: A primer for clinicians. <i>Depression and Anxiety</i> , <b>2019</b> , 36, 1004-1025	8.4	17
99	E.01.01 Pharmacological treatment of resistant OCD. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, S32	1.2	
98	Early intervention for obsessive compulsive disorder: An expert consensus statement. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 549-565	1.2	54
97	Neuroimaging findings as predictors of treatment outcome of psychotherapy in anxiety disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2019</b> , 91, 60-71	5.5	13
96	Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , <b>2018</b> , 23, 59-66	1.8	22
95	12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 970-979	1.2	14
94	Prevalence of hoarding behaviours and excessive acquisition in users of online classified advertisements. <i>Psychiatry Research</i> , <b>2018</b> , 270, 194-197	9.9	5
93	Manifesto for a European research network into Problematic Usage of the Internet. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 1232-1246	1.2	115
92	Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?. <i>Depression and Anxiety</i> , <b>2017</b> , 34, 1006-1017	8.4	54
91	There is an app for that! The current state of mobile applications (apps) for DSM-5 obsessive-compulsive disorder, posttraumatic stress disorder, anxiety and mood disorders. <i>Depression and Anxiety</i> , <b>2017</b> , 34, 526-539	8.4	129
90	Refractory social anxiety disorder. <i>Journal of Psychiatry and Neuroscience</i> , <b>2017</b> , 42, E1-E2	4.5	0
89	Placebo response in trichotillomania. <i>International Clinical Psychopharmacology</i> , <b>2017</b> , 32, 350-355	2.2	4
88	The Treatment of Refractory Generalized Anxiety Disorder. <i>Current Treatment Options in Psychiatry</i> , <b>2017</b> , 4, 404-417	3.1	0
87	Obsessive-compulsive disorder in the elderly: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>European Psychiatry</i> , <b>2017</b> , 45, 36-40	6	11
86	An Update on the Relationship Between the Gut Microbiome and Obsessive-Compulsive Disorder. <i>Psychiatric Annals</i> , <b>2017</b> , 47, 542-551	0.5	5

85	The use of waitlists as control conditions in anxiety disorders research. <i>Journal of Psychiatric Research</i> , <b>2016</b> , 83, 112-120	5.2	32
84	Standards of care for obsessive-compulsive disorder centres. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2016</b> , 20, 204-8	2.4	11
83	Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2016</b> , 20, 210-7	2.4	34
82	New treatment models for compulsive disorders. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, 877-84	1.2	14
81	AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Depression and Anxiety</i> , <b>2016</b> , 33, 728-36	8.4	20
80	"WHAT'S BUGGING THE GUT IN OCD?" A REVIEW OF THE GUT MICROBIOME IN OBSESSIVE-COMPULSIVE DISORDER. <i>Depression and Anxiety</i> , <b>2016</b> , 33, 171-8	8.4	46
79	Hoarding in users of online classified advertisements. <i>European Neuropsychopharmacology</i> , <b>2016</b> , 26, S622-S623	1.2	
78	In the wake of a possible mistake: Security motivation, checking behavior, and OCD. <i>Journal of Behavior Therapy and Experimental Psychiatry</i> , <b>2015</b> , 49, 133-140	2.6	8
77	Increased activity of frontal and limbic regions to emotional stimuli in children at-risk for anxiety disorders. <i>Psychiatry Research - Neuroimaging</i> , <b>2015</b> , 233, 9-17	2.9	12
76	Internet screening for anxiety disorders: Treatment-seeking outcomes in a three-month follow-up study. <i>Psychiatry Research</i> , <b>2015</b> , 230, 689-94	9.9	2
75	Frontal EEG alpha activity and obsessive-compulsive behaviors in non-clinical young adults: a pilot study. <i>Frontiers in Psychology</i> , <b>2015</b> , 6, 1480	3.4	4
74	Topiramate augmentation in a patient with obsessive-compulsive disorder. <i>Journal of Psychiatry and Neuroscience</i> , <b>2015</b> , 40, E31-2	4.5	2
73	DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 487-93	8.4	85
72	Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. <i>Journal of Psychopharmacology</i> , <b>2014</b> , 28, 596-602	4.6	40
71	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i> , <b>2014</b> , 14 Suppl 1, S1	4.2	396
70	P.4.c.001 The use of augmentation strategies in treatment resistant anxiety disorders: a meta-analysis and systematic review. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S605-S606	1.2	
69	The human ortholog of acid-sensing ion channel gene ASIC1a is associated with panic disorder and amygdala structure and function. <i>Biological Psychiatry</i> , <b>2014</b> , 76, 902-10	7.9	57
68	Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>Comprehensive Psychiatry</i> , <b>2014</b> , 55, 1513-9	7.3	77

67	Influence of RGS2 on sertraline treatment for social anxiety disorder. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 1340-6	8.7	28
66	A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. <i>American Journal of Psychiatry</i> , <b>2014</b> , 171, 44-53	11.9	38
65	Response to Silberman. <i>American Journal of Psychiatry</i> , <b>2014</b> , 171, 795-6	11.9	
64	The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>European Neuropsychopharmacology</i> , <b>2013</b> , 23, 865-71	1.2	40
63	Development of a brief version of the Social Phobia Inventory using item response theory: the Mini-SPIN-R. <i>Behavior Therapy</i> , <b>2013</b> , 44, 651-61	4.8	6
62	N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: A case series. <i>Journal of Obsessive-Compulsive and Related Disorders</i> , <b>2013</b> , 2, 48-52	1.7	16
61	Panic attacks in generalized anxiety disorder. <i>Journal of Nervous and Mental Disease</i> , <b>2013</b> , 201, 52-5	1.8	5
60	P.4.a.010 Adult attention deficit hyperactivity disorder and anxiety disorder comorbidity: prevalence in a clinical sample. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, S362-S363	1.2	
59	P.4.e.007 Internet screening for anxiety disorders and effects on treatment-seeking three months later. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, S376-S377	1.2	
58	Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add?. <i>Journal of Anxiety Disorders</i> , <b>2012</b> , 26, 665-72	10.9	25
57	When too much is not enough: obsessive-compulsive disorder as a pathology of stopping, rather than starting. <i>PLoS ONE</i> , <b>2012</b> , 7, e30586	3.7	44
56	Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?. <i>International Clinical Psychopharmacology</i> , <b>2012</b> , 27, 321-5	2.2	16
55	Serotonin reuptake and receptor blockers <b>2012</b> , 26-47		
54	Adult attention deficit hyperactivity disorder in an anxiety disorders population. <i>CNS Neuroscience and Therapeutics</i> , <b>2011</b> , 17, 221-6	6.8	36
53	Frontal Brain Oscillatory Coupling in Children of Parents With Social Phobia: A Pilot Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , <b>2011</b> , 23, 111-114	2.7	29
52	The impact of changing diagnostic criteria in posttraumatic stress disorder in a Canadian epidemiologic sample. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 1034-41	4.6	10
51	The psychology of potential threat: properties of the security motivation system. <i>Biological Psychology</i> , <b>2010</b> , 85, 331-7	3.2	35
50	The prevalence of migraine headaches in an anxiety disorders clinic sample. <i>CNS Neuroscience and Therapeutics</i> , <b>2010</b> , 16, 76-82	6.8	24

49	The burden of anxiety disorders on the family. <i>Journal of Nervous and Mental Disease</i> , <b>2010</b> , 198, 876-80	1.8	23
48	A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. <i>Current Psychiatry Reports</i> , <b>2010</b> , 12, 471-7	9.1	24
47	Potential use of Internet-based screening for anxiety disorders: a pilot study. <i>Depression and Anxiety</i> , <b>2010</b> , 27, 1006-10	8.4	12
46	A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1336-43	4.6	89
45	Paroxetine-induced increase in LDL cholesterol levels. <i>Journal of Psychopharmacology</i> , <b>2009</b> , 23, 826-30	4.6	15
44	Trichotillomania in youth: a retrospective case series. <i>Depression and Anxiety</i> , <b>2009</b> , 26, 661-5	8.4	5
43	Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. <i>Depression and Anxiety</i> , <b>2009</b> , 26, 1027-32	8.4	105
42	P.4.a.006 Internet-based screening of anxiety disorders. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, S588-S589	1.2	
41	Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. <i>International Clinical Psychopharmacology</i> , <b>2009</b> , 24, 87-96	2.2	68
40	Pharmacotherapy for social anxiety disorder: an update. <i>Israel Journal of Psychiatry and Related Sciences</i> , <b>2009</b> , 46, 53-61		5
39	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. <i>World Journal of Biological Psychiatry</i> , <b>2008</b> , 9, 248-312	3.8	496
38	Post-traumatic stress disorder in Canada. <i>CNS Neuroscience and Therapeutics</i> , <b>2008</b> , 14, 171-81	6.8	193
37	Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy. <i>Medical Psychiatry</i> , <b>2008</b> , 207-250		
36	Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 472-6	4.6	28
35	Behavioral and psychophysiological characteristics of children of parents with social phobia: a pilot study. <i>International Journal of Neuroscience</i> , <b>2007</b> , 117, 605-16	2	9
34	Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2007</b> , 68, 288-95	4.6	25
33	Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. <i>Depression and Anxiety</i> , <b>2006</b> , 23, 1-5	8.4	92
32	An evaluation of paroxetine in generalised social anxiety disorder. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 819-30	4	3

31	Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. <i>BMC Psychiatry</i> , <b>2005</b> , 5, 5	4.2	83
30	Emerging treatments for child and adolescent social phobia: a review. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2005</b> , 15, 589-607	2.9	40
29	The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 1401-8	4.6	69
28	A PET provocation study of generalized social phobia. <i>Psychiatry Research - Neuroimaging</i> , <b>2004</b> , 132, 13-8	2.9	39
27	Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. <i>Drugs</i> , <b>2004</b> , 64, 2199-220	12.1	47
26	Predictors of response in generalized social phobia: effect of age of onset. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 42-8	1.7	27
25	Optimizing treatment in social phobia: a review of treatment resistance. <i>CNS Spectrums</i> , <b>2004</b> , 9, 753-62	1.8	25
24	An open trial of topiramate in the treatment of generalized social phobia. <i>Journal of Clinical Psychiatry</i> , <b>2004</b> , 65, 1674-8	4.6	48
23	WCA recommendations for the long-term treatment of social phobia. <i>CNS Spectrums</i> , <b>2003</b> , 8, 40-52	1.8	70
22	Quality of life and the anxiety disorders. <i>Journal of Anxiety Disorders</i> , <b>2003</b> , 17, 405-26	10.9	93
21	The impact of anxiety disorders on educational achievement. <i>Journal of Anxiety Disorders</i> , <b>2003</b> , 17, 561-70	10.9	309
20	Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder?. <i>Journal of Affective Disorders</i> , <b>2002</b> , 68, 59-65	6.6	12
19	Topiramate treatment for SSRI-induced weight gain in anxiety disorders. <i>Journal of Clinical Psychiatry</i> , <b>2002</b> , 63, 981-4	4.6	26
18	Pharmacotherapy of social anxiety disorder at the turn of the millennium. <i>Psychiatric Clinics of North America</i> , <b>2001</b> , 24, 783-803	3.1	11
17	The neurobiology of social phobia: from pharmacotherapy to brain imaging. <i>Current Psychiatry Reports</i> , <b>2000</b> , 2, 358-66	9.1	9
16	Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 2215-31	5.9	17
15	The potential role of haloperidol in the treatment of trichotillomania. <i>Journal of Affective Disorders</i> , <b>1999</b> , 56, 219-26	6.6	40
14	Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. <i>Depression and Anxiety</i> , <b>1999</b> , 10, 33-9	8.4	22

13	Selective Serotonin Reuptake Inhibitors in the Treatment of Social Phobia. <i>CNS Drugs</i> , <b>1999</b> , 11, 307-315	6.7	14
12	Childhood attention deficit/hyperactivity disorder in adults with anxiety disorders. <i>Psychological Medicine</i> , <b>1999</b> , 29, 515-25	6.9	64
11	Nefazodone in social phobia. <i>Journal of Clinical Psychiatry</i> , <b>1999</b> , 60, 96-100	4.6	25
10	101. A pilot study of PET in social phobia. <i>Biological Psychiatry</i> , <b>1998</b> , 43, S31	7.9	4
9	The relationship of behavioral inhibition and shyness to anxiety disorder. <i>Journal of Nervous and Mental Disease</i> , <b>1998</b> , 186, 425-31	1.8	77
8	A high-risk pilot study of the children of adults with social phobia. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>1996</b> , 35, 1511-7	7.2	86
7	Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. <i>Journal of Affective Disorders</i> , <b>1996</b> , 39, 115-21	6.6	74
6	Paroxetine in social phobia. <i>Journal of Clinical Psychiatry</i> , <b>1996</b> , 57, 519-22	4.6	35
5	Relationship of childhood sexual and physical abuse to anxiety disorders. <i>Journal of Nervous and Mental Disease</i> , <b>1995</b> , 183, 309-14	1.8	70
4	Sertraline in social phobia. <i>Journal of Affective Disorders</i> , <b>1994</b> , 31, 141-5	6.6	45
3	Fluoxetine efficacy in social phobia. <i>Journal of Clinical Psychiatry</i> , <b>1993</b> , 54, 27-32	4.6	93
2	Adverse effects of switching from fluoxetine to desipramine. <i>Canadian Journal of Psychiatry</i> , <b>1992</b> , 37, 278	4.8	4
1	Relationship of social phobia with other psychiatric illness. <i>Journal of Affective Disorders</i> , <b>1991</b> , 21, 93-9	6.6	137